国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

600420 国药现代

交易中 07-09 14:25:07

{"stockData":{"symbol":"600420","market":"SH","secType":"STK","nameCN":"国药现代","latestPrice":8.57,"timestamp":1783578307000,"preClose":8.7,"halted":0,"volume":7003490,"delay":0,"changeRate":-0.0149,"floatShares":1341000000,"shares":1341000000,"eps":0.5358,"marketStatus":"交易中","change":-0.13,"latestTime":"07-09 14:25:07","open":8.65,"high":8.78,"low":8.55,"amount":60501900,"amplitude":0.0264,"askPrice":8.58,"askSize":30,"bidPrice":8.57,"bidSize":306,"shortable":0,"etf":0,"ttmEps":0.5358,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1783580400000},"marketStatusCode":2,"adr":0,"adjPreClose":8.7,"symbolType":"stock","openAndCloseTimeList":[[1783560600000,1783567800000],[1783573200000,1783580400000]],"highLimit":9.57,"lowLimit":7.83,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1341172692,"isCdr":false,"pbRate":0.84,"roa":"--","peRate":15.994774,"roe":"1.0%","epsLYR":0.7021,"committee":0.776088,"marketValue":11494000000,"turnoverRate":0.0052,"status":1,"floatMarketCap":11494000000},"requestUrl":"/m/hq/s/600420","defaultTab":"news","newsList":[{"id":"2648657907","title":"国药现代：他克莫司胶囊本次无法参与竞标","url":"https://stock-news.laohu8.com/highlight/detail?id=2648657907","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648657907?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:18","pubTimestamp":1783070322,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：公司他克莫司胶囊‌刚获批一致性评价，还能赶上第12批集采吗国药现代回复：尊敬的投资者：您好！根据第12批国家集采相关政策，国药川抗的他克莫司胶囊本次无法参与竞标。该药品目前销售占比较小，2025年销售额占公司销售收入不足0.5%，对公司整体经营业绩不会造成重大影响。后续公司将充分利用好各地医保招标挂网、商业代理等渠道，积极维护开拓市场。感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300031569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0132","BK0020","600420","BK0010","BK0082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648945657","title":"国药现代：改良型新药布瑞哌唑口溶膜正处于临床试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2648945657","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648945657?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:18","pubTimestamp":1783070301,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代07月03日在投资者关系平台上答复投资者关心的问题。目前公司改良型新药布瑞哌唑口溶膜，正处于临床试验阶段。兽药领域，公司已有原料药阿莫西林、氨苄西林的相关销售，占公司整体收入比重较低。如涉及重大信息，公司将及时履行信息披露义务。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300031546.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0010","BK0082","BK0020","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648657950","title":"国药现代：走好内生+外延发展的双轮驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2648657950","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648657950?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:15","pubTimestamp":1783070130,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)07月03日在投资者关系平台上答复投资者关心的问题。投资者提问：不好意思，之前说话有点冲，毕竟整个大环境不好也不能怪公司，再说要并购也要有好的标的，要不然随便并购来的也是累赘，只有稳扎稳打才能立于不败之地国药现代回复：尊敬的投资者：感谢您的充分支持，您的信任是对公司最大的鼓励！公司将竭尽全力，提升经营质量、夯实核心竞争力，走好内生+外延发展的双轮驱动，以稳健的发展提升公司内在价值！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300031454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0010","BK0020","600420","BK0132","BK0239","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648657363","title":"国药现代：公司深耕抗感染、心血管等优势领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2648657363","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648657363?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:01","pubTimestamp":1783069261,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代07月03日在投资者关系平台上答复投资者关心的问题。对部分技术壁垒低、同质化严重的研发项目予以终止，将释放的资金集中投向核心治疗领域、特色制剂、儿童及罕见病用药等优势赛道。公司深耕抗感染、心血管等优势领域，积极拓宽拓深产品覆盖面，提升药物可及性，在儿童药、罕见病等方向有所布局。有关公司研发项目情况请关注公司定期报告，以及有关临时公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070300030776.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0132","600420","BK0010","BK0020","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503245","title":"国药现代：慢病领域是公司目前重点发展领域之一","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648503245?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:12","pubTimestamp":1782983543,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代07月02日在投资者关系平台上答复投资者关心的问题。慢病负担同样在加重。全国18岁以上成年人中，高血压患者超过2.45亿，糖尿病患者约1.4亿，这些人对营养管理有持续的、具体的需求。特医特食战略记得贵公司前几年提过要重点布局，现在也不了了之了？慢病领域是公司目前重点发展领域之一，也非常感谢您的诚挚建议！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200028381.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0239","BK0010","BK0082","600420","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648037525","title":"国药现代：头孢呋辛酯片等产品市占率居行业前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2648037525","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648037525?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:09","pubTimestamp":1782983363,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代07月02日在投资者关系平台上答复投资者关心的问题。在医药中间体及原料药领域，克拉维酸钾系列产品、7-ACA、6-APA出口市场份额稳居行业前三。在制剂产品方面，头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠、头孢克肟颗粒、硝苯地平控释片、盐酸米那普仑片、双氯芬酸钠缓释片、头孢地尼分散片等产品市占率均居行业前列。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200028206.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0020","600420","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648503755","title":"国药现代：坚持以提升经营质量和内在价值为核心","url":"https://stock-news.laohu8.com/highlight/detail?id=2648503755","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648503755?lang=zh_cn&edition=full","pubTime":"2026-07-02 17:09","pubTimestamp":1782983361,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代07月02日在投资者关系平台上答复投资者关心的问题。非常理解您的心情，公司对股价表现亦同样关切！公司将以投资者的关切为动力，更加努力，坚持以提升经营质量和内在价值为核心，促进投资价值合理反映。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200028198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0132","BK0020","600420","BK0082","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647534775","title":"国药现代(600420.SH)子公司他克莫司胶囊通过仿制药一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2647534775","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647534775?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:52","pubTimestamp":1782813135,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司控股子公司国药集团川抗制药有限公司，收到国家药品监督管理局核准签发的《药品补充申请批准通知书》，批准他克莫司胶囊(1mg)及新增0.5mg规格通过仿制药质量和疗效一致性评价(简称一致性评价)。据悉，他克莫司胶囊适用于预防肝脏或肾脏移植术后的移植物排斥反应，治疗肝脏或肾脏移植术后应用其他免疫抑制药物无法控制的移植物排斥反应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461223.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0132","BK0020","600420","BK0010","BK0082","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647433993","title":"股市必读：国药现代（600420）6月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2647433993","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647433993?lang=zh_cn&edition=full","pubTime":"2026-06-29 02:45","pubTimestamp":1782672311,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘，国药现代报收于7.78元，下跌3.71%，换手率0.89%，成交量11.91万手，成交额9394.95万元。公司公告汇总：控股子公司获玻璃酸钠滴眼液《药品注册证书》，规格为0.1%和0.3%，视同通过一致性评价，2025年全国公立医疗机构及城市药店销售额达21.23亿元。2025年全国公立医疗机构及城市药店销售额为21.23亿元。截至目前，项目累计研发投入约521.08万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062900000849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600420","BK0020","BK0082","BK0239","BK0010","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646358929","title":"国药现代：公司2025年度投资支付的现金为0","url":"https://stock-news.laohu8.com/highlight/detail?id=2646358929","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646358929?lang=zh_cn&edition=full","pubTime":"2026-06-26 16:54","pubTimestamp":1782464053,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)06月26日在投资者关系平台上答复投资者关心的问题。投资者提问：根据公开资料，公司2025年用于投资支付和取得子公司的现金支出约‌21.3亿元，但未公布具体投资公司股权，请问21亿主要投向哪些公司与项目国药现代回复：尊敬的投资者：您好！公司2025年度投资支付的现金为0，取得子公司及其他营业单位支付的现金净额为0，详见公司2025年度报告第88页。感谢您的关注。本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。责任编辑：刘浩然","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062600030688.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0132","600420","BK0239","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646387546","title":"国药现代(600420.SH)：玻璃酸钠滴眼液获药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2646387546","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646387546?lang=zh_cn&edition=full","pubTime":"2026-06-25 17:11","pubTimestamp":1782378679,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，公司控股子公司国药集团三益药业(芜湖)有限公司收到国家药品监督管理局核准签发的玻璃酸钠滴眼液《药品注册证书》。本次国药三益获得玻璃酸钠滴眼液药品注册证书并视同通过一致性评价，进一步丰富了公司眼用制剂产品群，形成更完整的眼科用药组合，有利于增强公司在眼科用药领域的综合市场竞争力，为公司未来发展带来积极影响。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1458700.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600420","BK0010","BK0132","BK0020","BK0239","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645832093","title":"国药现代（600420）披露下属子公司获得药品注册证书，6月23日股价上涨1.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645832093","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645832093?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:29","pubTimestamp":1782224954,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘，国药现代报收于8.39元，较前一交易日上涨1.45%，最新总市值为112.52亿元。该股当日开盘8.21元，最高8.57元，最低8.2元，成交额达9862.44万元，换手率为0.87%。近日，上海现代制药股份有限公司下属子公司国药集团工业有限公司和国药集团川抗制药有限公司分别收到国家药品监督管理局核准签发的《药品注册证书》。两品种均视同通过一致性评价，丰富公司产品线，提升市场竞争力，但对当期经营业绩无重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042654.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0132","600420","BK0239","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645881982","title":"国药现代(600420.SH)：盐酸纳布啡注射液、硫酸羟氯喹片获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2645881982","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645881982?lang=zh_cn&edition=full","pubTime":"2026-06-23 16:38","pubTimestamp":1782203932,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司下属子公司国药集团工业有限公司(简称国药工业)、国药集团川抗制药有限公司(简称国药川抗)，分别收到国家药品监督管理局核准签发的盐酸纳布啡注射液、硫酸羟氯喹片《药品注册证书》。盐酸纳布啡注射液广泛应用于缓解中至重度疼痛，也可作为复合麻醉时麻醉诱导。国药工业本次获批的适应症为作为镇痛药用于复合麻醉时的麻醉诱导。硫酸羟氯喹片主要用于治疗类风湿关节炎，青少年慢性关节炎，盘状和系统性红斑狼疮，以及由阳光引发或加剧的皮肤疾病。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：盐酸纳布啡注射液、硫酸羟氯喹片获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0132","BK0020","600420","BK0010","BK0082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644767355","title":"股市必读：国药现代（600420）6月16日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2644767355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644767355?lang=zh_cn&edition=full","pubTime":"2026-06-17 03:43","pubTimestamp":1781638987,"startTime":"0","endTime":"0","summary":"截至2026年6月16日收盘，国药现代报收于8.48元，下跌0.93%，换手率0.51%，成交量6.86万手，成交额5803.92万元。公司公告汇总：控股子公司获他氟前列素滴眼液《药品注册证书》，视同通过一致性评价，累计研发投入约805.83万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061700003387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0010","BK0082","BK0239","BK0132","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2643727571","title":"国药现代(600420.SH)子公司获得他氟前列素滴眼液药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2643727571","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2643727571?lang=zh_cn&edition=full","pubTime":"2026-06-15 16:12","pubTimestamp":1781511148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代(600420.SH)发布公告，近日，公司控股子公司国药集团三益药业(芜湖)有限公司收到国家药品监督管理局核准签发的他氟前列素滴眼液《药品注册证书》。他氟前列素滴眼液是一种用于降低眼压的药物，适用于降低开角型青光眼和高眼压症患者升高的眼压。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1454350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)子公司获得他氟前列素滴眼液药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0082","BK0020","BK0010","BK0239","BK0132","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642463670","title":"国药现代：目前国药新疆尚无在研新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2642463670","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642463670?lang=zh_cn&edition=full","pubTime":"2026-06-09 16:42","pubTimestamp":1780994541,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)06月09日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘，您好，最近子公司国药新疆制药新药研发进展如何？国药现代回复：尊敬的投资者：您好！目前国药新疆尚无在研新药，感谢您的关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060900027027.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0082","600420","BK0239","BK0132","BK0010"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640918765","title":"国药现代：聚焦临床价值与差异化竞争","url":"https://stock-news.laohu8.com/highlight/detail?id=2640918765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640918765?lang=zh_cn&edition=full","pubTime":"2026-06-02 15:37","pubTimestamp":1780385863,"startTime":"0","endTime":"0","summary":"证券之星消息，国药现代(600420)06月02日在投资者关系平台上答复投资者关心的问题。投资者提问：公司在26年提出要通过并购，积极推进外延发展，转眼5个月过去，公司对哪些方向的产品管线做了调研国药现代回复：尊敬的投资者：您好！公司聚焦临床价值与差异化竞争，以抗感染、麻醉及精神、慢病、专科等核心领域，聚优势、强能力，积极开展相关工作。公司坚持战略导向与效益导向并重，审慎论证资源匹配与投入节奏，确保项目发展路径既具前瞻性，更具可行性与持续性。如有重大信息，公司将严格按照信息披露规则及时公告。感谢关注！本文数据来源于上海证券交易所e互动，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200024163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0010","BK0239","BK0082","600420","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604494","title":"每周股票复盘：国药现代（600420）拟每股派现0.20元","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604494","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604494?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:52","pubTimestamp":1780170733,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘，国药现代报收于9.28元，较上周的9.08元上涨2.2%。本周，国药现代5月29日盘中最高价报9.29元。国药现代当前最新总市值124.46亿元，在化学制药板块市值排名39/150，在两市A股市值排名1648/5207。股权登记日为2026年6月2日，除权（息）日为2026年6月3日，现金红利发放日为2026年6月3日。个人股东持股期限超过1年的暂免征收个人所得税，QFII股东和沪港通投资者按10%税率代扣代缴所得税。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001131.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0082","BK0010","BK0020","600420","BK0239","BK0132"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638755639","title":"国药现代（600420）披露2025年年度权益分派实施公告，5月25日股价下跌0.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638755639","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638755639?lang=zh_cn&edition=full","pubTime":"2026-05-25 22:47","pubTimestamp":1779720435,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘，国药现代报收于9.0元，较前一交易日下跌0.88%，最新总市值为120.71亿元。该股当日开盘9.08元，最高9.13元，最低8.97元，成交额达5387.44万元，换手率为0.44%。近日，国药现代发布《2025年年度权益分派实施公告》：每股派发现金红利0.20元（含税），以公司总股本1,341,172,692股为基数，合计派发现金红利268,234,538.40元。个人股东持股期限超过1年的暂免征收个人所得税，QFII股东和沪港通投资者按10%税率代扣代缴所得税。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500034281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0020","BK0132","BK0010","BK0082","BK0239","600420"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637834643","title":"国药现代(600420.SH)：伊布替尼胶囊获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2637834643","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637834643?lang=zh_cn&edition=full","pubTime":"2026-05-21 16:16","pubTimestamp":1779351361,"startTime":"0","endTime":"0","summary":"智通财经APP讯，国药现代 发布公告，近日，公司收到国家药品监督管理局核准签发的伊布替尼胶囊《药品注册证书》。据悉，伊布替尼胶囊是一种口服的小分子布鲁顿酪氨酸激酶抑制剂，属于靶向治疗药物。作为全球首个获批上市的BTK抑制剂，它于2013年在美国首次获准用于临床，并于2017年进入中国市场。根据米内网数据库，伊布替尼胶囊2025年在全国公立医疗机构及城市药店销售额为3.98亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444456.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"国药现代(600420.SH)：伊布替尼胶囊获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","600420","BK0132","BK0010","BK0020","BK0082"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783578312738,"stockEarnings":[{"period":"1week","weight":0.0571},{"period":"1month","weight":-0.0225},{"period":"3month","weight":-0.1417},{"period":"6month","weight":-0.1603},{"period":"1year","weight":-0.1602},{"period":"ytd","weight":-0.1196}],"compareEarnings":[{"period":"1week","weight":-0.0344},{"period":"1month","weight":0.0029},{"period":"3month","weight":0.0012},{"period":"6month","weight":-0.0363},{"period":"1year","weight":0.1354},{"period":"ytd","weight":0.0005}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海现代制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"36225人(较上一季度增加1.00%)","perCapita":"37023股","listingDate":"2004-06-16","address":"上海市浦东新区建陆路378号","registeredCapital":"134117万元","survey":"　　上海现代制药股份有限公司的主营业务是医药产品研发、生产与销售。公司的主要产品是6-APA、7-ACA、D-7ACA、青霉素工业钾盐、头孢曲松钠粗盐、氨苄西林酸。在制剂产品方面，根据米内网数据库显示，公司头孢呋辛酯片、注射用甲泼尼龙琥珀酸钠国内市场占有率稳居行业第一；头孢克肟颗粒市场份额进一步提升，展现出良好的增长态势；硝苯地平控释片、盐酸米那普仑片市场占有率稳居仿制药企业第一。","listedPrice":8.08},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"国药现代,600420,国药现代股票,国药现代股票老虎,国药现代股票老虎国际,国药现代行情,国药现代股票行情,国药现代股价,国药现代股市,国药现代股票价格,国药现代股票交易,国药现代股票购买,国药现代股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"国药现代(600420)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供国药现代(600420)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}